comparemela.com
  1. Home
  2. Live Updates
  3. Medical Products - Breaking News

Latest Breaking News On - Medical products - Page 17 : comparemela.com

New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting

V-INITIATE trial demonstrates that early initiation with Leqvio, prior to guideline-recommended ezetimibe, for ASCVD patients unable to achieve LDL-C goal on statin therapy alone led to significant LDL-C reduction vs. clinician-determined usual care (60% vs. 7% respectively)1 A significantly greater proportion of the ASCVD patients receiving Leqvio achieved guideline-recommended LDL-C goal vs. the usual care arm […]

United-states
South-korea
Switzerland
China
Netherlands
Amsterdam
Noord-holland
Japan
America
American
Swiss
Han

Baxter International Inc. (NYSE:BAX) Shares Sold by Cubic Asset Management LLC

Baxter International Inc. (NYSE:BAX) Shares Sold by Cubic Asset Management LLC
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Indiana
United-states
America
Quarter-for-baxter-international
News-ratings-for-baxter-international-daily
Baxter-international-inc
Indiana-trust-investment-management
Wealth-management
Baxter-international-dividend-announcement
Baxter-international-company-profile
Citigroup

Novartis Pharma AG: New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting

Novartis Pharma AG: New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United-states
South-korea
Amsterdam
Noord-holland
Netherlands
Switzerland
Japan
China
Han
America
Swiss
American

New Novartis data show early addition of twice-yearly*

V-INITIATE trial demonstrates that early initiation with Leqvio, prior to guideline-recommended ezetimibe, for ASCVD patients unable to achieve LDL-C goal.

United-states
South-korea
China
Switzerland
Netherlands
Amsterdam
Noord-holland
Japan
America
Swiss
Han
American

New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting

New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United-states
South-korea
Netherlands
Amsterdam
Noord-holland
China
Switzerland
Japan
Han
American
America
Swiss
© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.